Tags

Type your tag names separated by a space and hit enter

Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
J Sex Med. 2013 Jul; 10(7):1790-9.JS

Abstract

INTRODUCTION

Vulvar and vaginal atrophy (VVA) is a chronic medical condition experienced by many postmenopausal women. Symptoms include dyspareunia (pain with intercourse), vaginal dryness, and irritation and may affect sexual activities, relationships, and activities of daily life.

AIM

The aim of this study is to characterize postmenopausal women's experience with and perception of VVA symptoms, interactions with healthcare professionals (HCPs), and available treatment options.

METHODS

An online survey was conducted in the United States in women from KnowledgePanel(®) , a 56,000-member probability-selected Internet panel projectable to the overall US population. Altogether, 3,046 postmenopausal women with VVA symptoms (the largest US cohort of recent surveys) responded to questions about their knowledge of VVA, impact of symptoms on their activities, communication with HCPs, and use of available treatments.

MAIN OUTCOME MEASURES

Percent is calculated as the ratio of response over total responding for each question for all and stratified participants.

RESULTS

The most common VVA symptoms were dryness (55% of participants), dyspareunia (44%), and irritation (37%). VVA symptoms affected enjoyment of sex in 59% of participants. Additionally, interference with sleep, general enjoyment of life, and temperament were reported by 24%, 23%, and 23% of participants, respectively. Few women attributed symptoms to menopause (24%) or hormonal changes (12%). Of all participants, 56% had ever discussed VVA symptoms with an HCP and 40% currently used VVA-specific topical treatments (vaginal over-the-counter [OTC] products [29%] and vaginal prescription therapies [11%]). Of those who had discussed symptoms with an HCP, 62% used OTC products. Insufficient symptom relief and inconvenience were cited as major limitations of OTC products and concerns about side effects and cancer risk limited use of topical vaginal prescription therapies.

CONCLUSIONS

VVA symptoms are common in postmenopausal women. Significant barriers to treatment include lack of knowledge about VVA, reluctance to discuss symptoms with HCPs, safety concerns, inconvenience, and inadequate symptom relief from available treatments.

Authors+Show Affiliations

Department of Reproductive Biology, Case Western University, Cleveland, OH, USA. Sheryl.kingsberg@uhhospitals.orgNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23679050

Citation

Kingsberg, Sheryl A., et al. "Vulvar and Vaginal Atrophy in Postmenopausal Women: Findings From the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey." The Journal of Sexual Medicine, vol. 10, no. 7, 2013, pp. 1790-9.
Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-9.
Kingsberg, S. A., Wysocki, S., Magnus, L., & Krychman, M. L. (2013). Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. The Journal of Sexual Medicine, 10(7), 1790-9. https://doi.org/10.1111/jsm.12190
Kingsberg SA, et al. Vulvar and Vaginal Atrophy in Postmenopausal Women: Findings From the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey. J Sex Med. 2013;10(7):1790-9. PubMed PMID: 23679050.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. AU - Kingsberg,Sheryl A, AU - Wysocki,Susan, AU - Magnus,Leslie, AU - Krychman,Michael L, Y1 - 2013/05/16/ PY - 2013/5/18/entrez PY - 2013/5/18/pubmed PY - 2014/6/27/medline KW - Dyspareunia KW - Postmenopausal Women KW - Sexual Relationships KW - Survey KW - Vaginal Dryness KW - Vulvar and Vaginal Atrophy SP - 1790 EP - 9 JF - The journal of sexual medicine JO - J Sex Med VL - 10 IS - 7 N2 - INTRODUCTION: Vulvar and vaginal atrophy (VVA) is a chronic medical condition experienced by many postmenopausal women. Symptoms include dyspareunia (pain with intercourse), vaginal dryness, and irritation and may affect sexual activities, relationships, and activities of daily life. AIM: The aim of this study is to characterize postmenopausal women's experience with and perception of VVA symptoms, interactions with healthcare professionals (HCPs), and available treatment options. METHODS: An online survey was conducted in the United States in women from KnowledgePanel(®) , a 56,000-member probability-selected Internet panel projectable to the overall US population. Altogether, 3,046 postmenopausal women with VVA symptoms (the largest US cohort of recent surveys) responded to questions about their knowledge of VVA, impact of symptoms on their activities, communication with HCPs, and use of available treatments. MAIN OUTCOME MEASURES: Percent is calculated as the ratio of response over total responding for each question for all and stratified participants. RESULTS: The most common VVA symptoms were dryness (55% of participants), dyspareunia (44%), and irritation (37%). VVA symptoms affected enjoyment of sex in 59% of participants. Additionally, interference with sleep, general enjoyment of life, and temperament were reported by 24%, 23%, and 23% of participants, respectively. Few women attributed symptoms to menopause (24%) or hormonal changes (12%). Of all participants, 56% had ever discussed VVA symptoms with an HCP and 40% currently used VVA-specific topical treatments (vaginal over-the-counter [OTC] products [29%] and vaginal prescription therapies [11%]). Of those who had discussed symptoms with an HCP, 62% used OTC products. Insufficient symptom relief and inconvenience were cited as major limitations of OTC products and concerns about side effects and cancer risk limited use of topical vaginal prescription therapies. CONCLUSIONS: VVA symptoms are common in postmenopausal women. Significant barriers to treatment include lack of knowledge about VVA, reluctance to discuss symptoms with HCPs, safety concerns, inconvenience, and inadequate symptom relief from available treatments. SN - 1743-6109 UR - https://www.unboundmedicine.com/medline/citation/23679050/Vulvar_and_vaginal_atrophy_in_postmenopausal_women:_findings_from_the_REVIVE__REal_Women's_VIews_of_Treatment_Options_for_Menopausal_Vaginal_ChangEs__survey_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1743-6095(15)30431-8 DB - PRIME DP - Unbound Medicine ER -